Antengene Corporation Limited (6996) reported that the Department of Health of the Hong Kong Special Administrative Region approved two supplemental New Drug Applications for XPOVIO® (selinexor). The new indications include XPOVIO® in combination with bortezomib and dexamethasone for adult patients with multiple myeloma who have received at least one prior therapy, and XPOVIO® as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma following at least two lines of systemic therapy for those not eligible for haematopoietic cell transplant.

According to the announcement dated December 3, 2025, XPOVIO® is now cleared for broader application in multiple myeloma and diffuse large B-cell lymphoma. Antengene’s pipeline ranges from preclinical to commercial-stage programs, which include several in-house discovered projects such as ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

In addition to Hong Kong, XPOVIO® has also obtained approval in multiple markets, including Mainland China, Taiwan, Macau, South Korea, Singapore, Malaysia, Thailand, Indonesia, and Australia. The drug has been incorporated into national insurance schemes in several of these countries. These approvals form part of Antengene’s broader strategy to address significant unmet needs in complex hematological malignancies and solid tumors worldwide.